On this page
The review in brief
This remains a status review rather than a recommendation to begin a Semax purchase. Request confirmation of ordering availability, clinical eligibility, formulation and final charges. Until those align across the provider’s program, keep it out of active price rankings. Treat the contradiction as unresolved, without assuming either permanent discontinuation or a completed launch.
Open the provider record
- Published price
- No active Semax price established
- Product description
- Homepage says coming soon; some educational pages describe nasal access
- Access
- Ordering not confirmed
In the published record
- Homepage flags the launch limitation
- First-party educational coverage is available
Questions still open
- Availability statements conflict
- Active formulation and quote are not established
The homepage sets a cautious starting point
The telos rx homepage groups Semax with peptide protocols marked coming soon and says they are not yet available to order. That is the clearest reason not to present an immediately obtainable Semax program here. A visible illustration or educational link does not override the ordering qualification.
The educational pages do not agree
A pharmacy-verification article says Semax is not offered, while a newer Selank explainer describes telos rx prescribing a compounded Semax nasal spray. These are conflicting first-party statements. We cannot resolve them by choosing whichever creates the more attractive comparison row; ask the service to confirm the current status directly.
Do not invent a payable package
Without a confirmed active pathway, there is no established Semax quote to compare. The cost of NAD+, another peptide or a general care service cannot substitute for the missing offer. Likewise, a nasal reference in educational copy does not establish the exact label a patient would receive.
Why this matters to the comparison
The Rx waitlist review concerns an explicit launch-in-progress page. telos rx adds a different problem: inconsistent descriptions across its own pages. In either case, the remedy is a current, product-specific confirmation before assuming access, not a calculation based on another provider’s bottle.
Separate study knowledge from commercial readiness
Our rat brain-exposure article explains a scientific boundary between administration and biological exposure. A similar discipline helps with service descriptions: knowing how a molecule is studied does not show that a pharmacy currently dispenses a particular formulation. The two questions need different evidence. The OurView availability review examines a price table paired with a coming-soon button. It shows why an attractive published amount cannot resolve a contradictory ordering status. Obtain confirmation before comparing either service as an active offer.
Our position
This remains a status review rather than a recommendation to begin a Semax purchase. Request confirmation of ordering availability, clinical eligibility, formulation and final charges. Until those align across the provider’s program, keep it out of active price rankings. Treat the contradiction as unresolved, without assuming either permanent discontinuation or a completed launch.
Evidence index
Original research and documented service details.
- telos rx official Semax informationCompany website
- telos rx pharmacy-verification status statementCompany website
- telos rx Selank explainer with conflicting Semax statementCompany website